8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2023 / Single-center, prospective, randomized, single-blind clinical trial
Adults with an increased 10-year risk of ASCVD were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice for 28 days. A total of 190 participants completed the trial. Rosuvastatin achieved a greater percent LDL-C reduction than all supplements and placebo (P < 0.001), with a -35.2% difference compared with placebo (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo, and adverse event rates were similar across groups.
Laffin LJ, Bruemmer D, Garcia M, et al. J Am Coll Cardiol, 2023. PMID 36351465
2017 / Randomized controlled trial
Patients with coronary artery disease were randomized to receive garlic powder or dummy pills twice each day across a 3-month period. Ultrasound evaluation showed that flow-mediated dilation improved by 50.7% in the garlic group compared to the control group (p = 0.016). High-sensitivity C-reactive protein declined significantly with garlic but did not differ from control, and no alterations occurred in macrophage cholesterol efflux or mononuclear cell gene expression.
Mahdavi-Roshan M, Mirmiran P, Arjmand M, et al. Anatol J Cardiol, 2017. PMID 28554988
2016 / Randomized crossover trial
A randomized crossover pilot trial evaluated 26 adults with type 2 diabetes who consumed 1,200 mg of aged garlic extract or placebo daily for 4 weeks. Supplementation had no significant effect on insulin resistance or metabolic measures. In addition, aged garlic extract did not significantly alter markers of endothelial function, oxidative stress, or vascular inflammation in this high-risk population.
Atkin M, Laight D, Cummings MH J Diabetes Complications, 2016. PMID 26954484
2013 / Randomized controlled trial
In a trial of 56 patients with coronary artery disease, participants received garlic powder tablets or placebo twice daily for 3 months. Garlic resulted in minor intima-media thickness variation (-0.009 ± 0.007 mm), whereas placebo showed an increase (0.04 ± 0.01 mm), reflecting a significant between-group divergence (p < 0.001). Lipid and lipoprotein concentrations did not differ significantly between treatments.
Mahdavi-Roshan M, Zahedmehr A, Mohammad-Zadeh A, et al. Nutr Health, 2013. PMID 25573347
1993 / Randomized controlled trial
Patients with stage II peripheral arterial occlusive disease received either 800 mg of garlic powder daily or a placebo for 12 weeks, with both groups undergoing physical therapy twice weekly. The increase in walking distance was significantly higher (P < 0.05) in the garlic group (by 46 m, from 161.0 +/- 65.1 to 207.1 +/- 85.0 m) compared with the placebo group (by 31 m, from 172.0 +/- 60.9 to 203.1 +/- 72.8 m). Diastolic blood pressure, spontaneous thrombocyte aggregation, plasma viscosity, and cholesterol concentration also decreased significantly, while body weight was maintained. The garlic-specific increase in walking distance did not appear until the 5th week of treatment, coinciding with a decrease in spontaneous thrombocyte aggregation.
Kiesewetter H, Jung F, Jung EM, et al. Clin Investig, 1993. PMID 8508009